What are the sensitivity and specificity of GeneXpert (Xpert Mycobacterium tuberculosis/Rifampicin) for detecting Mycobacterium tuberculosis and rifampicin resistance in sputum, broncho‑alveolar lavage, cerebrospinal fluid, urine, stool, and tissue specimens?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

GeneXpert MTB/RIF Sensitivity and Specificity Across Different Specimen Types

For pulmonary TB, GeneXpert demonstrates excellent performance on sputum (sensitivity 85-96%, specificity 98-99%), but performance drops substantially for extrapulmonary specimens, with sensitivity ranging from 33% for non-respiratory samples to 60-89% for specific extrapulmonary sites. 1, 2, 3

Respiratory Specimens

Sputum (Standard Specimen)

  • AFB smear-positive sputum: Sensitivity 96-100%, specificity 85-99% 1, 4, 3
  • AFB smear-negative sputum: Sensitivity 66-77%, specificity 80-98% 1, 5, 3
  • Overall pooled sensitivity: 85-95%, specificity 98% 1, 4, 2
  • Sputum provides the highest diagnostic yield and should be the preferred specimen type 2

Other Respiratory Specimens

  • Gastric aspirate/juice: Sensitivity 94% (95% CI 0.84-0.99), comparable to sputum 2
  • Bronchoalveolar lavage (BAL): Performance similar to sputum but specific data limited in guidelines 1
  • These specimens are particularly useful in children or patients unable to produce sputum 1

Extrapulmonary Specimens

Overall Performance

  • Non-respiratory specimens (pooled): Sensitivity 33-89%, specificity 95-99.7% 3, 6
  • The dramatic drop in sensitivity compared to respiratory specimens makes negative results unreliable for excluding TB 3, 6

Specific Extrapulmonary Sites

Cerebrospinal Fluid (CSF)

  • Sensitivity 56-62%, specificity approximately 98% 5
  • Critical limitation: False-negative rate of 40-50% in TB meningitis 5
  • A negative result cannot exclude TB meningitis; empiric treatment should not be withheld based on negative GeneXpert alone 5

Pleural Fluid

  • Sensitivity 56-62%, specificity approximately 98% 5
  • Performance is suboptimal for tuberculous pleuritis 2

Lymph Node Tissue/Biopsy

  • Sensitivity 60-63%, specificity 33% 3
  • Major pitfall: Extremely low specificity makes this the worst-performing specimen type 3
  • Care must be taken when interpreting GeneXpert results from lymph node tissue 3

Bone and Joint Specimens

  • Both biopsy and joint fluid demonstrate high accuracy for bone and joint TB 2
  • Specific sensitivity/specificity values not provided in guidelines but performance described as satisfactory 2

Urine and Stool

  • Limited data in guidelines; not recommended as primary diagnostic specimens 5
  • May be useful in disseminated/miliary TB as part of multi-specimen strategy 5

Rifampicin Resistance Detection

  • Sensitivity for rifampicin resistance: >97% when performed on single specimen, increases to >97% on three specimens 1
  • Specificity for rifampicin resistance: >97-99% 1, 4
  • Critical caveat: Positive predictive value is low in populations with low prevalence of drug resistance (<2% MDR-TB prevalence) 1
  • All rifampicin resistance results must be confirmed by phenotypic culture-based drug susceptibility testing 5, 7, 6

Special Populations

HIV-Positive Patients

  • Pooled sensitivity: 79% (lower than HIV-negative patients) 4
  • Performance remains acceptable but false-negative rate is higher 8, 4

Miliary/Disseminated TB

  • Sensitivity: Only 50-60% across all specimen types 5
  • False-negative rate: 40-50% 5
  • Critical management point: Negative GeneXpert cannot exclude miliary TB; empiric treatment should be initiated based on clinical suspicion 5

Clinical Interpretation Algorithm

When GeneXpert is POSITIVE:

  • Presume TB and initiate treatment immediately (PPV >95% for respiratory specimens) 5, 4
  • Rifampicin resistance results should guide initial therapy but require phenotypic confirmation 7, 6

When GeneXpert is NEGATIVE:

  • AFB smear-positive but GeneXpert negative: Check for inhibitors, collect new specimen 1, 5
  • Smear-negative, GeneXpert negative, high clinical suspicion: Do NOT exclude TB; proceed with empiric treatment while awaiting culture 1, 5
  • Extrapulmonary specimens: A negative result is particularly unreliable; culture remains essential 5, 3, 6

Critical Pitfalls to Avoid

  • Never rely on GeneXpert alone for extrapulmonary TB: Sensitivity is too low (33-89%) to rule out disease 3, 6
  • Never withhold treatment for miliary TB based on negative GeneXpert: False-negative rate approaches 50% 5
  • Never start MDR-TB regimen based solely on GeneXpert rifampicin resistance: Phenotypic confirmation is mandatory 7
  • Always send specimens for culture regardless of GeneXpert result: Culture remains the gold standard and provides comprehensive drug susceptibility data 1, 5, 3
  • Lymph node tissue has unacceptably low specificity (33%): Interpret positive results with extreme caution 3

Specimen Collection Strategy

  • Collect multiple specimens (≥3 sputum samples on different days) to maximize sensitivity 7
  • For suspected extrapulmonary TB, obtain specimens from multiple sites (respiratory, urine, blood, relevant body fluids) 5
  • Reserve sufficient specimen volume for culture before performing GeneXpert 5
  • Results should be available within 48 hours of collection 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.